Connection

Michael Hallek to Aged

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Aged.
Michael Hallek
Connection Strength
0.197
Aged
  1. Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. Anticancer Res. 2019 May; 39(5):2591-2598.
    View in: PubMed
    Score: 0.015
  2. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
    View in: PubMed
    Score: 0.014
  3. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
    View in: PubMed
    Score: 0.014
  4. [Which drugs in Hemato-Oncology are Unnecessary or Inappropriate for Use in the Elderly?] Dtsch Med Wochenschr. 2018 02; 143(4):244-252.
    View in: PubMed
    Score: 0.013
  5. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
    View in: PubMed
    Score: 0.013
  6. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705.
    View in: PubMed
    Score: 0.013
  7. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
    View in: PubMed
    Score: 0.011
  8. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
    View in: PubMed
    Score: 0.011
  9. [Elderly patients in clinical trials: new fitness-adapted concepts]. Internist (Berl). 2007 Nov; 48(11):1232-7.
    View in: PubMed
    Score: 0.007
  10. Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring bias. Medicine (Baltimore). 2021 Jul 30; 100(30):e26720.
    View in: PubMed
    Score: 0.004
  11. COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
    View in: PubMed
    Score: 0.004
  12. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun; 63(6):528-534.
    View in: PubMed
    Score: 0.004
  13. Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. Ann Hematol. 2019 Nov; 98(11):2605-2607.
    View in: PubMed
    Score: 0.004
  14. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
    View in: PubMed
    Score: 0.004
  15. Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019 09; 104(9):1798-1803.
    View in: PubMed
    Score: 0.004
  16. HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection. 2019 Apr; 47(2):293-300.
    View in: PubMed
    Score: 0.004
  17. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 12; 58:7-13.
    View in: PubMed
    Score: 0.004
  18. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
    View in: PubMed
    Score: 0.004
  19. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep. 2018 10 08; 8(1):14941.
    View in: PubMed
    Score: 0.004
  20. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
    View in: PubMed
    Score: 0.004
  21. Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients. In Vivo. 2018 Jul-Aug; 32(4):819-824.
    View in: PubMed
    Score: 0.003
  22. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
    View in: PubMed
    Score: 0.003
  23. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
    View in: PubMed
    Score: 0.003
  24. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 04 16; 11(1):55.
    View in: PubMed
    Score: 0.003
  25. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018 02 15; 9(1):697.
    View in: PubMed
    Score: 0.003
  26. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP. BMC Cancer. 2018 01 10; 18(1):62.
    View in: PubMed
    Score: 0.003
  27. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2018 03; 53(3):255-263.
    View in: PubMed
    Score: 0.003
  28. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 01 15; 142(2):322-333.
    View in: PubMed
    Score: 0.003
  29. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 09 21; 130(12):1477-1480.
    View in: PubMed
    Score: 0.003
  30. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 10; 31(10):2251-2253.
    View in: PubMed
    Score: 0.003
  31. Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2244-2247.
    View in: PubMed
    Score: 0.003
  32. Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer. 2017 06; 108:134-139.
    View in: PubMed
    Score: 0.003
  33. Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest. 1997 Feb; 27(2):121-7.
    View in: PubMed
    Score: 0.003
  34. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.